Stock MNMD MIND MEDICINE (MINDMED) INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Mind Medicine (MindMed) Inc.

Equities

MNMD

CA60255C8850

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
8.22 USD -4.97% Intraday chart for Mind Medicine (MindMed) Inc. -11.23% +124.59%
May. 13 Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating MT
May. 08 Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating
MT
Mind Medicine (MindMed) Inc. - New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting Show Growing Burden and Impact of Generalized Anxiety Disorder in the US
AQ
MindMed to Participate at May Investor Conferences
BU
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
BU
Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024
MindMed Reports First Quarter 2024 Financial Results and Business Updates
BU
Mind Medicine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
MindMed ISPOR 2024: Work Productivity and Activity Impairment Associated with Generalized Anxiety Disorder among Adults in the United States
PU
MindMed ISPOR 2024: Health-related Quality of Life Associated with Generalized Anxiety Disorder among Adults in the United States
PU
MindMed ISPOR 2024: Health Care Resource Use Associated with Generalized Anxiety Disorder among Adults in the United States
PU
MindMed APA 2024: Screening Adults in the US General Population to Detect Cases of Undiagnosed Generalized Anxiety Disorder
PU
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
BU
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
BU
MindMed to Present at Upcoming May Medical Conferences
BU
Leerink Partners Starts Mind Medicine (MindMed) With Outperform Rating, $20 Price Target
MT
MindMed to Present at Upcoming April Medical Conferences
BU
MindMed Announces Voluntary Delisting from Cboe Canada
BU
Mind Medicine Inc. announced that it has received $75 million in funding from Deep Track Capital, LP, Commodore Capital
CI
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
BU
RBC Raises Price Target on Mind Medicine (MindMed) to $22 From $15, Keeps Outperform, Speculative Risk
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MNMD Stock
  4. News Mind Medicine (MindMed) Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW